Vanquishing disease and improving lives is the raison d’etre of drug development. It’s a quest that biomedicine has been increasingly winning. Yet, such success is often hard fought. Whether it is a result of a pipeline setback, asset transactions, or replacing sunsetting product revenues; to succeed, at some point, most companies will need to pivot their pipeline. The likelihood of a pivot is greater in intractable therapeutic areas that have high failure rates, such as conditions of the brain. This session will capture the learnings of biopharmaceutical executives who have had to pivot and rebuild pipelines to succeed, including a case study from Ovid, a neurotherapeutics company:
Key topics will include:
- Building a pipeline with optionality versus binary risk
- Identifying where to play and how to get there
- Transacting creatively to get deals done
- Creating a pipeline that will deliver value, successively
